Ofatumumab Versus Rituximab in Children With Steroid and Calcineurin Inhibitor-dependent Idiopathic Nephrotic Syndrome: an Open-label, Randomized, Controlled, Superiority Trial.
Phase of Trial: Phase II
Latest Information Update: 08 Sep 2015
At a glance
- Drugs Ofatumumab (Primary)
- Indications Nephrotic syndrome
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 10 Jun 2015 Planned End Date changed from 1 Mar 2019 to 1 May 2019, as reported by ClinicalTrials.gov record.
- 10 Jun 2015 Planned primary completion date changed from 1 Apr 2018 to 1 Jun 2018, as reported by ClinicalTrials.gov record.